PPCB — Propanc Biopharma Balance Sheet
0.000.00%
- $20.23m
- $21.89m
Annual balance sheet for Propanc Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.002 | 0.004 | 0.01 | 0.021 | 0.012 |
| Net Total Receivables | 0.004 | 0.002 | 0.003 | 0.003 | 0.005 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.007 | 0.015 | 0.019 | 0.025 | 8.35 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.004 | 0.065 | 0.039 | 0.018 | 0.059 |
| Other Long Term Assets | |||||
| Total Assets | 0.013 | 0.082 | 0.06 | 0.072 | 19.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.08 | 3.06 | 3.16 | 3.79 | 5.58 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.08 | 3.11 | 3.18 | 3.85 | 5.73 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -3.07 | -3.02 | -3.12 | -3.78 | 13.9 |
| Total Liabilities & Shareholders' Equity | 0.013 | 0.082 | 0.06 | 0.072 | 19.6 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |